Cargando…

Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100

We have previously demonstrated the immunogenicity of VGX-3100, a multicomponent DNA immunotherapy for the treatment of Human Papillomavirus (HPV)16/18-positive CIN2/3 in a phase 1 clinical trial. Here, we report on the ability to boost immune responses with an additional dose of VGX-3100. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morrow, Matthew P, Kraynyak, Kimberly A, Sylvester, Albert J, Shen, Xuefei, Amante, Dinah, Sakata, Lindsay, Parker, Lamar, Yan, Jian, Boyer, Jean, Roh, Christian, Humeau, Laurent, Khan, Amir S, Broderick, Kate, Marcozzi-Pierce, Kathleen, Giffear, Mary, Lee, Jessica, Trimble, Cornelia L, Kim, J Joseph, Sardesai, Niranjan Y, Weiner, David B, Bagarazzi, Mark L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5147865/ https://www.ncbi.nlm.nih.gov/pubmed/28054033 http://dx.doi.org/10.1038/mto.2016.25

Ejemplares similares

DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial
por: Humeau, Laurent, et al.
Publicado: (2014)

Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL
por: Bhuyan, Prakash K., et al.
Publicado: (2020)

Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results
por: Aggarwal, Charu, et al.
Publicado: (2015)

Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population
por: Hollenberg, Rebecca K., et al.
Publicado: (2019)

Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis
por: Aggarwal, Charu, et al.
Publicado: (2020)

HPV E2, E4, E5 drive alternative carcinogenic pathways in HPV positive cancers
por: Ren, Shuling, et al.
Publicado: (2020)

HPV DNA methylation at the early promoter and E1/E2 integrity: A comparison between HPV16, HPV18 and HPV45 in cervical cancer
por: Amaro-Filho, Sérgio Menezes, et al.
Publicado: (2018)

Delineation of the HPV11E6 and HPV18E6 Pathways in Initiating Cellular Transformation
por: Mwapagha, Lamech M., et al.
Publicado: (2017)

HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women
por: Bruno, Maria Teresa, et al.
Publicado: (2018)

Identification of variants and therapeutic epitopes in HPV-33/HPV-58 E6 and E7 in Southwest China
por: He, Jiaoyu, et al.
Publicado: (2019)

A Non-oncogenic HPV 16 E6/E7 Vaccine Enhances Treatment of HPV Expressing Tumors
por: Wieking, Bryant G., et al.
Publicado: (2012)

Fusion of CTLA-4 with HPV16 E7 and E6 Enhanced the Potency of Therapeutic HPV DNA Vaccine
por: Gan, Lili, et al.
Publicado: (2014)

The Expression of HPV E6/E7 mRNA In Situ Hybridization in HPV Typing-negative Cervical Cancer
por: Xu, Yating, et al.
Publicado: (2023)

HPV E6, E6AP and cervical cancer
por: Beaudenon, Sylvie, et al.
Publicado: (2008)

E6/E7 and E6(*) From HPV16 and HPV18 Upregulate IL-6 Expression Independently of p53 in Keratinocytes
por: Artaza-Irigaray, Cristina, et al.
Publicado: (2019)

Diversity of cervicovaginal human papillomavirus (HPV) genotypes and naturally occurring E6/E7 DNA polymorphisms of HPV-16 in Ghana
por: Kaba, Gladys, et al.
Publicado: (2023)

HPV16 E6/E7 -based mRNA vaccine is therapeutic in mice bearing aggressive HPV-positive lesions
por: Zhou, Kun, et al.
Publicado: (2023)

HPV11 E6 mutation by overexpression of APOBEC3A and effects of interferon-ω on APOBEC3s and HPV11 E6 expression in HPV11.HaCaT cells
por: Wang, Yongfang, et al.
Publicado: (2017)

Role of HPV16 E1 in cervical carcinogenesis
por: Baedyananda, Fern, et al.
Publicado: (2022)

Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers
por: Chang, J T-C, et al.
Publicado: (2010)

Establishment of immunoassay for detecting HPV16 E6 and E7 RNA
por: Ding, Sen, et al.
Publicado: (2015)

Flavonol and imidazole derivatives block HPV16 E6 activities and reactivate apoptotic pathways in HPV(+) cells
por: Yuan, C-H, et al.
Publicado: (2016)

Do or Die: HPV E5, E6 and E7 in Cell Death Evasion
por: Skelin, Josipa, et al.
Publicado: (2022)

The high-risk HPV E6 target scribble (hScrib) is required for HPV E6 expression in cervical tumour-derived cell lines
por: Kranjec, Christian, et al.
Publicado: (2016)

Development and validation of a multiplex qPCR assay for detection and relative quantification of HPV16 and HPV18 E6 and E7 oncogenes
por: Bordigoni, Alexia, et al.
Publicado: (2021)

Evolution and Taxonomic Classification of Alphapapillomavirus 7 Complete Genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70
por: Chen, Zigui, et al.
Publicado: (2013)

HPV16 E6 upregulates Aurora A expression
por: Guo, Yi, et al.
Publicado: (2016)

HPV 16 E7 alters translesion synthesis signaling
por: Wendel, Sebastian O., et al.
Publicado: (2022)

Analysis of E2 gene integrity in HPV16 and HPV58 viruses isolated from women with cervical pathology
por: González-Losa, María del R, et al.
Publicado: (2016)

A novel HPV16 E7-affitoxin for targeted therapy of HPV16-induced human cervical cancer
por: Jiang, Pengfei, et al.
Publicado: (2018)

HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection
por: Beachler, Daniel C., et al.
Publicado: (2016)

Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67
por: Chen, Zigui, et al.
Publicado: (2011)

Phylogeny and polymorphism in the E6 and E7 of human papillomavirus: alpha-9 (HPV16, 31, 33, 52, 58), alpha-5 (HPV51), alpha-6 (HPV53, 66), alpha-7 (HPV18, 39, 59, 68) and alpha-10 (HPV6, 44) in women from Shanghai
por: Zhao, Junwei, et al.
Publicado: (2019)

HPV18 E7 induces the over-transcription of eIF4E gene in cervical cancer
por: Pang, Tianyun, et al.
Publicado: (2015)

Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy
por: Xiong, Chengjie, et al.
Publicado: (2022)

COV-VGX: An automated COVID-19 detection system using X-ray images and transfer learning
por: Saha, Prottoy, et al.
Publicado: (2021)

Potent cellular immune responses after therapeutic immunization of HIV-positive patients with the PENNVAX®-B DNA vaccine in a Phase I Trial
por: Tebas, P, et al.
Publicado: (2012)

Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years
por: Paaso, Anna, et al.
Publicado: (2015)

Deep Sequencing of HPV16 E6 Region Reveals Unique Mutation Pattern of HPV16 and Predicts Cervical Cancer
por: Ai, Wenchao, et al.
Publicado: (2022)

5-aza-2′-deoxycytidine (DAC) treatment downregulates the HPV E6 and E7 oncogene expression and blocks neoplastic growth of HPV-associated cancer cells
por: Stich, Maximilian, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n5e1vmagleiq27mbmgvm4argsv